DAITO PHARMACEUTICAL CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,214 JPY | -1.16% |
|
-2.72% | +16.22% |
| Sales 2024 * | 48.3B 312M | Sales 2025 * | 52B 336M | Capitalization | 33.86B 219M |
|---|---|---|---|---|---|
| Net income 2024 * | 3.67B 23.7M | Net income 2025 * | 4B 25.83M | EV / Sales 2024 * | 0.7 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.65 x |
| P/E ratio 2024 * |
9.53
x | P/E ratio 2025 * |
8.75
x | Employees | 1,011 |
| Yield 2024 * |
2.71% | Yield 2025 * |
2.8% | Free-Float | 78.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.16% | ||
| 1 week | -2.72% | ||
| Current month | -0.54% | ||
| 1 month | -11.51% | ||
| 3 months | +6.03% | ||
| 6 months | +15.13% | ||
| Current year | +16.22% |
1 week
2 123.00
2 251.00
1 month
2 123.002 573.00
Current year
1 868.002 573.00
1 year
1 803.002 573.00
3 years
1 803.003 413.64
5 years
1 803.004 145.45
10 years
1 292.564 145.45
| Managers | Title | Age | Since |
|---|---|---|---|
Kiyotaka Kido
PSD | President | - | - |
Eiichi Takada
CTO | Chief Tech/Sci/R&D Officer | - | - |
Masuo Nomura
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yasunobu Otsuga
BRD | Director/Board Member | 73 | 75-02-28 |
Michio Tsuda
BRD | Director/Board Member | 76 | 71-03-31 |
Hitoshi Hori
BRD | Director/Board Member | 70 | 99-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 19 M€ | +11.32% | ||
| 0.01% | 17 M€ | +14.54% | - | |
| 0.01% | 140,441 M€ | +19.11% | ||
| 0.01% | 63,295 M€ | +19.16% | - | |
| 0.01% | 20,360 M€ | +17.89% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 2,214 | -1.16% | 35,100 |
| 24-06-03 | 2,240 | +0.63% | 47,300 |
| 24-05-31 | 2,226 | +2.06% | 47,600 |
| 24-05-30 | 2,181 | -1.13% | 52,500 |
| 24-05-29 | 2,206 | -1.87% | 78,000 |
Delayed Quote Japan Exchange, June 04, 2024 at 02:00 am EDT
More quotes
Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.
Sector
Pharmaceuticals
Calendar
2024-07-11
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,214
JPY
Average target price
3,010
JPY
Spread / Average Target
+35.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.22% | 219M | |
| +13.53% | 41.95B | |
| +22.20% | 22.53B | |
| +17.35% | 14.11B | |
| +45.62% | 12.5B | |
| -0.05% | 6.79B | |
| -9.44% | 6.75B | |
| -8.87% | 5.73B | |
| +14.55% | 5.6B | |
| +4.00% | 4.95B |
- Stock Market
- Equities
- 4577 Stock
